Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder

• Published in: Biomedicines 2020-12, Vol.8 (12), p.601
• Main Authors: Yavropoulou, Maria P, Vaios, Vasilios, Makras, Polyzois, Georgianos, Panagiotis, Batas, Anastasios, Tsalikakis, Dimitrios, Tzallas, Alexandros, Ntritsos, Georgios, Roumeliotis, Stefanos, Eleftheriadis, Theodoros, Liakopoulos, Vassilios
• Format: Article
• Language: English
• Subjects: Absorptiometry; Bone diseases; Bone loss; Bone mineral density; Bone turnover; Calcium metabolism; Cancellous bone; circulating microRNAs; CKD-MBD; Diabetes; Dual energy X-ray absorptiometry; end stage renal disease; Fractures; Hemodialysis; Hospitals; Immunoassay; Kidney diseases; Metabolism; MicroRNAs; miRNA; Mortality; Osteoblasts; Osteoclasts; Osteoporosis; Pathophysiology; trabecular bone score; Transplants & implants
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines8120601

The pathophysiology of chronic kidney disease-mineral and bone disorder (CKD-MBD) is complex and multifactorial. Recent studies have identified a link between microRNAs (miRNAs) and bone loss. In this study, we investigated the expression of miRNAs in CKD-MBD. In this case-control study, we included thirty patients with CKD-MBD (cases) and 30 age- and gender-matched healthy individuals (controls). Bone mineral density (BMD) and trabecular bone score (TBS) evaluation was performed with dual X-ray absorptiometry. The selected panel of miRNAs included: hsa-miRNA-21-5p; hsa-miRNA-23a-3p; hsa-miRNA-24-2-5p; hsa-miRNA-26a-5p; hsa-miRNA-29a-3; hsa-miRNA-124-3p; hsa-miRNA-2861. The majority of cases had low BMD values. The relative expression of miRNA-21-5p was 15 times lower [fold regulation (FR): -14.7 ± 8.1, = 0.034), miRNA-124-3p, 6 times lower (FR: -5.9 ± 4, = 0.005), and miRNA-23a-3p, 4 times lower (FR: -3.8 ± 2.0, = 0.036) in cases compared to controls. MiRNA-23a-3p was significantly and inversely correlated with TBS, adjusted for calcium metabolism and BMD values (beta = -0.221, = 0.003, 95% CI -0.360, -0,081) in cases. In a receiver operating characteristic (ROC) analysis, expression of miRNA-124-3p demonstrated 78% sensitivity and 83% specificity in identifying CKD patents with osteoporosis. Serum expression of miRNAs related to osteoblasts (miRNA-23a-3p) and osteoclasts (miRNA-21-5p, miRNA-124-3p) is significantly altered in patients with CKD-MBD.